Compass Therapeutics Inc (NASDAQ: CMPX) has seen a rise in its stock price by 3.79 in relation to its previous close of 2.24. However, the company has experienced a -5.49% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-27 that Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 – a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the first quarter 2025. Supported initiation of an Investigator Sponsored Study (IST) evaluating tovecimig in patients with BTC in the first-line setting, with patient dosing expected in the first quarter 2025.
Is It Worth Investing in Compass Therapeutics Inc (NASDAQ: CMPX) Right Now?
Moreover, the 36-month beta value for CMPX is 1.10. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CMPX is 80.70M and currently, short sellers hold a 4.58% of that float. On March 21, 2025, CMPX’s average trading volume was 1.51M shares.
CMPX’s Market Performance
CMPX stock saw a decrease of -5.49% in the past week, with a monthly decline of -24.51% and a quarterly a decrease of 51.96%. The volatility ratio for the week is 7.27%, and the volatility levels for the last 30 days are 8.62% for Compass Therapeutics Inc (CMPX). The simple moving average for the last 20 days is -11.06% for CMPX stock, with a simple moving average of 31.31% for the last 200 days.
Analysts’ Opinion of CMPX
Many brokerage firms have already submitted their reports for CMPX stocks, with Guggenheim repeating the rating for CMPX by listing it as a “Buy.” The predicted price for CMPX in the upcoming period, according to Guggenheim is $12 based on the research report published on February 24, 2025 of the current year 2025.
Piper Sandler, on the other hand, stated in their research note that they expect to see CMPX reach a price target of $12. The rating they have provided for CMPX stocks is “Overweight” according to the report published on February 19th, 2025.
D. Boral Capital gave a rating of “Buy” to CMPX, setting the target price at $32 in the report published on December 23rd of the previous year.
CMPX Trading at -17.57% from the 50-Day Moving Average
After a stumble in the market that brought CMPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.01% of loss for the given period.
Volatility was left at 8.62%, however, over the last 30 days, the volatility rate increased by 7.27%, as shares sank -20.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +62.24% upper at present.
During the last 5 trading sessions, CMPX fell by -5.69%, which changed the moving average for the period of 200-days by +70.59% in comparison to the 20-day moving average, which settled at $2.61. In addition, Compass Therapeutics Inc saw 60.34% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CMPX
Current profitability levels for the company are sitting at:
- -15.01 for the present operating margin
- 0.75 for the gross margin
The net margin for Compass Therapeutics Inc stands at -12.93. The total capital return value is set at -0.38. Equity return is now at value -36.07, with -33.22 for asset returns.
Based on Compass Therapeutics Inc (CMPX), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -6.99. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -29.59.
Currently, EBITDA for the company is -48.47 million with net debt to EBITDA at 0.56. When we switch over and look at the enterprise to sales, we see a ratio of 78.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.96.
Conclusion
To wrap up, the performance of Compass Therapeutics Inc (CMPX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
